HomeSHTDF • OTCMKTS
add
Sinopharm Group Co Ltd
Previous close
$2.53
Year range
$2.11 - $2.65
Market cap
60.45B HKD
Avg Volume
58.00
P/E ratio
-
Dividend yield
-
Primary exchange
HKG
Market news
Financials
Income Statement
Revenue
Net income
| (CNY) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 145.44B | -1.53% |
Operating expense | 6.37B | -6.94% |
Net income | 1.85B | 16.88% |
Net profit margin | 1.27 | 18.69% |
Earnings per share | — | — |
EBITDA | 4.66B | 3.57% |
Effective tax rate | 24.66% | — |
Balance Sheet
Total assets
Total liabilities
| (CNY) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 38.77B | — |
Total assets | 418.38B | — |
Total liabilities | 286.21B | — |
Total equity | 132.17B | — |
Shares outstanding | 3.12B | — |
Price to book | 0.10 | — |
Return on assets | 2.46% | — |
Return on capital | 4.71% | — |
Cash Flow
Net change in cash
| (CNY) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | 1.85B | 16.88% |
Cash from operations | -4.97B | 26.15% |
Cash from investing | 781.72M | -19.99% |
Cash from financing | -4.04B | -162.10% |
Net change in cash | -8.22B | -12.59% |
Free cash flow | -1.34B | — |
About
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.
Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
Founded
2003
Website
Employees
100,251
